Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
12.08
-0.58 (-4.58%)
At close: May 15, 2026, 4:00 PM EDT
12.11
+0.03 (0.25%)
After-hours: May 15, 2026, 7:37 PM EDT
Immunic Employees
Immunic had 92 employees as of December 31, 2025. The number of employees increased by 1 or 1.10% compared to the previous year.
Employees
92
Change
1
Growth
1.10%
Revenue / Employee
n/a
Profits / Employee
-$1,133,554
Market Cap
164.55M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 92 | 1 | 1.10% |
| Sep 30, 2025 | 90 | 5 | 5.88% |
| Jun 30, 2025 | 90 | 5 | 5.88% |
| Mar 31, 2025 | 90 | 10 | 12.50% |
| Dec 31, 2024 | 91 | 14 | 18.18% |
| Sep 30, 2024 | 85 | 5 | 6.25% |
| Jun 30, 2024 | 85 | 10 | 13.33% |
| Mar 31, 2024 | 80 | 7 | 9.59% |
| Dec 31, 2023 | 77 | 11 | 16.67% |
| Sep 30, 2023 | 80 | 15 | 23.08% |
| Jun 30, 2023 | 75 | 15 | 25.00% |
| Mar 31, 2023 | 73 | 18 | 32.73% |
| Dec 31, 2022 | 66 | 11 | 20.00% |
| Sep 30, 2022 | 65 | 13 | 25.00% |
| Jun 30, 2022 | 60 | 15 | 33.33% |
| Mar 31, 2022 | 55 | 15 | 37.50% |
| Dec 31, 2021 | 55 | 27 | 96.43% |
| Sep 30, 2021 | 52 | 24 | 85.71% |
| Jun 30, 2021 | 45 | - | - |
| Mar 31, 2021 | 40 | 14 | 53.85% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| ProQR Therapeutics | 187 |
| Heron Therapeutics | 128 |
| Acumen Pharmaceuticals | 61 |
| Equillium | 35 |
| Enlivex | 34 |
| AN2 Therapeutics | 21 |
| Black Diamond Therapeutics | 21 |
IMUX News
- 1 day ago - Immunic price target lowered to $19 from $26 at Roth Capital - TheFly
- 3 days ago - Immunic reports Q1 EPS ($1.08), consensus (96c) - TheFly
- 3 days ago - Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update - PRNewsWire
- 12 days ago - Immunic initiated with an Outperform at LifeSci Capital - TheFly
- 16 days ago - Immunic to Participate in Investor and Medical Conferences in May - PRNewsWire
- 16 days ago - Immunic price target adjusted to $22 from $5 at H.C. Wainwright - TheFly
- 18 days ago - Immunic CMO Andreas Muehler to depart, Michael Panzara to succeed - TheFly
- 18 days ago - Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D. - PRNewsWire